191 related articles for article (PubMed ID: 25045800)
1. Benomyl, aldehyde dehydrogenase, DOPAL, and the catecholaldehyde hypothesis for the pathogenesis of Parkinson's disease.
Casida JE; Ford B; Jinsmaa Y; Sullivan P; Cooney A; Goldstein DS
Chem Res Toxicol; 2014 Aug; 27(8):1359-61. PubMed ID: 25045800
[TBL] [Abstract][Full Text] [Related]
2. Rotenone decreases intracellular aldehyde dehydrogenase activity: implications for the pathogenesis of Parkinson's disease.
Goldstein DS; Sullivan P; Cooney A; Jinsmaa Y; Kopin IJ; Sharabi Y
J Neurochem; 2015 Apr; 133(1):14-25. PubMed ID: 25645689
[TBL] [Abstract][Full Text] [Related]
3. Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease.
Goldstein DS; Sullivan P; Holmes C; Miller GW; Alter S; Strong R; Mash DC; Kopin IJ; Sharabi Y
J Neurochem; 2013 Sep; 126(5):591-603. PubMed ID: 23786406
[TBL] [Abstract][Full Text] [Related]
4. Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson disease.
Fitzmaurice AG; Rhodes SL; Lulla A; Murphy NP; Lam HA; O'Donnell KC; Barnhill L; Casida JE; Cockburn M; Sagasti A; Stahl MC; Maidment NT; Ritz B; Bronstein JM
Proc Natl Acad Sci U S A; 2013 Jan; 110(2):636-41. PubMed ID: 23267077
[TBL] [Abstract][Full Text] [Related]
5. The Catecholaldehyde Hypothesis for the Pathogenesis of Catecholaminergic Neurodegeneration: What We Know and What We Do Not Know.
Goldstein DS
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34206133
[TBL] [Abstract][Full Text] [Related]
6. Products of oxidative stress inhibit aldehyde oxidation and reduction pathways in dopamine catabolism yielding elevated levels of a reactive intermediate.
Jinsmaa Y; Florang VR; Rees JN; Anderson DG; Strack S; Doorn JA
Chem Res Toxicol; 2009 May; 22(5):835-41. PubMed ID: 19388687
[TBL] [Abstract][Full Text] [Related]
7. The catecholaldehyde hypothesis: where MAO fits in.
Goldstein DS
J Neural Transm (Vienna); 2020 Feb; 127(2):169-177. PubMed ID: 31807952
[TBL] [Abstract][Full Text] [Related]
8. Dihydroxyphenylacetaldehyde Lowering Treatment Improves Locomotor and Neurochemical Abnormalities in the Rat Rotenone Model: Relevance to the Catecholaldehyde Hypothesis for the Pathogenesis of Parkinson's Disease.
Khashab R; Gutman-Sharabi N; Shabtai Z; Landau R; Halperin R; Fay-Karmon T; Leibowitz A; Sharabi Y
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569897
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the oxidative metabolism of 3,4-dihydroxyphenylacetaldehyde, a reactive intermediate of dopamine metabolism, by 4-hydroxy-2-nonenal.
Florang VR; Rees JN; Brogden NK; Anderson DG; Hurley TD; Doorn JA
Neurotoxicology; 2007 Jan; 28(1):76-82. PubMed ID: 16956664
[TBL] [Abstract][Full Text] [Related]
10. Lipid peroxidation products inhibit dopamine catabolism yielding aberrant levels of a reactive intermediate.
Rees JN; Florang VR; Anderson DG; Doorn JA
Chem Res Toxicol; 2007 Oct; 20(10):1536-42. PubMed ID: 17887726
[TBL] [Abstract][Full Text] [Related]
11. Decreased vesicular storage and aldehyde dehydrogenase activity in multiple system atrophy.
Goldstein DS; Sullivan P; Holmes C; Kopin IJ; Sharabi Y; Mash DC
Parkinsonism Relat Disord; 2015 Jun; 21(6):567-72. PubMed ID: 25829070
[TBL] [Abstract][Full Text] [Related]
12. Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinson's disease.
Goldstein DS; Sullivan P; Cooney A; Jinsmaa Y; Sullivan R; Gross DJ; Holmes C; Kopin IJ; Sharabi Y
J Neurochem; 2012 Dec; 123(6):932-43. PubMed ID: 22906103
[TBL] [Abstract][Full Text] [Related]
13. 3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells.
Lamensdorf I; Eisenhofer G; Harvey-White J; Nechustan A; Kirk K; Kopin IJ
Brain Res; 2000 Jun; 868(2):191-201. PubMed ID: 10854571
[TBL] [Abstract][Full Text] [Related]
14. Catechols in post-mortem brain of patients with Parkinson disease.
Goldstein DS; Sullivan P; Holmes C; Kopin IJ; Basile MJ; Mash DC
Eur J Neurol; 2011 May; 18(5):703-10. PubMed ID: 21073636
[TBL] [Abstract][Full Text] [Related]
15. Aldehyde dehydrogenase inhibition generates a reactive dopamine metabolite autotoxic to dopamine neurons.
Doorn JA; Florang VR; Schamp JH; Vanle BC
Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1(0 1):S73-5. PubMed ID: 24262193
[TBL] [Abstract][Full Text] [Related]
16. Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinson's disease.
Wey MC; Fernandez E; Martinez PA; Sullivan P; Goldstein DS; Strong R
PLoS One; 2012; 7(2):e31522. PubMed ID: 22384032
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Monoamine Oxidase Inhibitors in Decreasing Production of the Autotoxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde in PC12 Cells.
Goldstein DS; Jinsmaa Y; Sullivan P; Holmes C; Kopin IJ; Sharabi Y
J Pharmacol Exp Ther; 2016 Feb; 356(2):483-92. PubMed ID: 26574516
[TBL] [Abstract][Full Text] [Related]
18. Identification of aldehyde dehydrogenase 1A1 modulators using virtual screening.
Kotraiah V; Pallares D; Toema D; Kong D; Beausoleil E
J Enzyme Inhib Med Chem; 2013 Jun; 28(3):489-94. PubMed ID: 22380773
[TBL] [Abstract][Full Text] [Related]
19. The rat rotenone model reproduces the abnormal pattern of central catecholamine metabolism found in Parkinson's disease.
Landau R; Halperin R; Sullivan P; Zibly Z; Leibowitz A; Goldstein DS; Sharabi Y
Dis Model Mech; 2022 Jan; 15(1):. PubMed ID: 34842277
[TBL] [Abstract][Full Text] [Related]
20. Inactivation of glyceraldehyde-3-phosphate dehydrogenase by the dopamine metabolite, 3,4-dihydroxyphenylacetaldehyde.
Vanle BC; Florang VR; Murry DJ; Aguirre AL; Doorn JA
Biochem Biophys Res Commun; 2017 Oct; 492(2):275-281. PubMed ID: 28830811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
